Refining a preclinical model of viral myocarditis in accordance with biotech standards
Animal Models and Experimental Medicine · 2026
DOI: 10.1002/ame2.70263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2026. Verfasst von Jonas Stewen und 9 weiteren Autor:innen. Beteiligte Einrichtung: CSL Innovation GmbH, Marburg, Germany. Hauptthemen laut MEDLINE: Myocarditis, Disease Models, Animal, Coxsackievirus Infections. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Innovation GmbH.
Abstract (Originalsprache)
Background
Viral myocarditis is a clinically relevant inflammatory heart disease that can progress to dilated cardiomyopathy and heart failure. However, preclinical models often suffer from limited translational relevance and high animal burden.
Methods
This study aimed to refine a murine model of Coxsackievirus B3 (CVB3)‐induced myocarditis by integrating dietary and imaging innovations to improve animal welfare, data quality, and clinical applicability. BALB/cJ mice were infected with heart‐passaged CVB3 and monitored for up to 56 days. A hydrolyzed amino acid diet was introduced to mitigate CVB3‐induced pancreatitis and associated weight loss. Cardiac function was assessed using 1D, 2D, and 4D echocardiography, including speckle‐tracking strain analysis.
Results
The refined diet significantly reduced animal health burden, reduced weight loss, and stabilized blood glucose, during development of cardiac inflammation and fibrosis. 4D echocardiography provided a highly sensitive and reproducible detection of systolic dysfunction, while strain analysis revealed early and regional myocardial impairment, closely mirroring clinical myocarditis phenotypes. Histopathological and AI‐based analyses confirmed dose‐ and time‐dependent inflammation and fibrosis, with peak inflammation at day 7 and persistent abnormalities through day 56.
Conclusions
In summary, this model offers a robust and ethically optimized platform for translational research and therapeutic development in inflammatory cardiomyopathies, aligned with the principles of the 3Rs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CSL Innovation GmbH, Marburg, Germany.
ORCID-Profile: Juan E Camacho Londoño
Förderung
- CSL Innovation GmbH
Zitieren
APA
Stewen, J., Riedesel, J., Stein, J., Greene, B. H., Rohde, S., Suess, S., Keiner, B., Panjwani, P., Ponnuswamy, P., & Camacho Londoño, J. E. (2026). Refining a preclinical model of viral myocarditis in accordance with biotech standards. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.70263
Vancouver
Stewen J, Riedesel J, Stein J, Greene BH, Rohde S, Suess S, et al. Refining a preclinical model of viral myocarditis in accordance with biotech standards. Animal Models and Experimental Medicine. 2026. doi:10.1002/ame2.70263
BibTeX
@article{Stewen2026,
author = {Stewen, Jonas and Riedesel, Julia and Stein, Juliane and Greene, Brandon H and Rohde, Svenja and Suess, Sonja and Keiner, Bjoern and Panjwani, Priya and Ponnuswamy, Padmapriya and Camacho Londoño, Juan E},
title = {Refining a preclinical model of viral myocarditis in accordance with biotech standards},
journal = {Animal Models and Experimental Medicine},
year = {2026},
doi = {10.1002/ame2.70263}
}
EUVIMED